Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-07-12
2004-10-05
McKenzie, Thomas (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S327000, C544S328000
Reexamination Certificate
active
06800630
ABSTRACT:
TECHNICAL FIELD
The present invention relates to a novel pyrimidine derivative having an antitumor activity, a cytostatic activity, and an inhibitory activity against a signal derived from Ras oncogene products.
BACKGROUND ART
The oncogene “ras” such as H-ras, K-ras, and N-ras is mutated and activated in many of neoplasms. The “Ras”, the products of ras oncogene, strongly concerns tumorigenesis caused by acceleration of cell cycle and induction of expression of many of genes associated with a malignant conversion such as a vascular endothelial growth factor and type-IV collagenase. Especially, it is found that there is highly frequent ras mutation in solid tumor such as pancreatic cancer (>80%), colon cancer (>40%), and lung cancer (>20%) which are difficult to be cured by using existing chemotherapeutics. Therefore, it is considered that Ras is one of the most important target molecules in the development of the chemotherapeutics against them.
A farnesyl-protein-transferase (FPT) inhibitor (FPTI) is known as chemotherapeutics of which target are Ras (WO95/13059, WO95/25086, WO95/25092, WO95/34535, U.S. Pat. No. 5,608,067, and JP-A-7-112930).
In the cells expressing activated Ras, the excess signals reach cell nucleus through some signaling pathways and some signal transmitter molecules such as MAPK (Mitogen Activated Protein Kinase) and PI3K (Phosphatidylinositol-3-Kinase). The signals activate the transcription factors such as AP1 (Activator Protein-1) and ETS (E26 transformation specific) in the cell nucleus and then they induce the expression of many genes related to malignant features through transcription activation element such as Ras Responsive Element (RRE). Therefore, it is possible to repress the malignant conversion of the cancer cells, when the signal transmission (a signal derived from ras oncogene products) is inhibited. Inhibitors of a signal derived from Ras oncogene products, of which basic structure is similar to that of the compounds of the present invention, are described in WO00/04014.
DISCLOSURE OF INVENTION
In the above situation, the inventors of the present invention have studied on the antitumor agent having an inhibitory activity against a signal derived from Ras oncogene products.
The activation of gene expression through RRE is in proportion to a signal derived from Ras and the signal can be measured by the amount of its expression. The inventors of the present invention artificially made cells having activated Ras wherein expression of firefly luciferase gene, reporter gene, is regulated by RRE and carried out a screening of the inhibitors taking luciferase activity shown by the cells as an index of signals through Ras. As a result, the inventors of the present invention found that a series of pyrimidine derivatives have a strong inhibitory activity against a signal derived from Ras oncogene products.
The present invention relates to I) a compound represented by the formula (I):
wherein R
1
, R
2
, R
3
, and R
4
are each independently hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, an optionally substituted non-aromatic heterocyclic group, acyl, optionally substituted amino, alkyloxy, hydroxy, cyano, or nitro; or
R
1
and R
2
, R
3
and R
4
, and R
2
and R
3
each taken together with the adjacent nitrogen atom form the same or different 3- to 7-membered ring optionally containing O, N, or S, provided that R
1
and R
2
, and R
3
and R
4
do not form a ring when R
2
and R
3
taken together form a ring;
R
5
and R
6
are each independently hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkyloxy, alkylthio, optionally substituted alkyloxycarbonyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, hydroxy, mercapto, optionally substituted amino, carboxy, cyano, or nitro;
R
B
and R
C
are each independently hydrogen atom, alkyl, or alkyloxy; provided that in the case of both of R
B
and R
C
are hydrogen atom, R
1
is hydrogen atom or alkyl, R
2
is optionally substituted amino, alkyloxy, hydroxy, cyano, or nitro; and R
3
and R
4
are each independently hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted non-aromatic heterocyclic group, acyl, optionally substituted amino, alkyloxy, hydroxy, cyano, or nitro; or R
3
and R
4
each taken together with the adjacent nitrogen atom form the same or different 3- to 7-membered ring optionally containing O, N, or S;
X is —N(R
7
)—, —NH—NH—, —O—, or —S— wherein R
7
is hydrogen atom or optionally substituted alkyl;
Y is optionally substituted 5-membered non-aromatic heterocycle-diyl or optionally substituted 5-membered heteroaryl-diyl;
Z is optionally substituted aryl or optionally substituted heteroaryl; its optical active compound, its prodrug thereof, or their pharmaceutically acceptable salt, or their solvate.
In more detail, the present invention relates to II)-XVI):
II) a compound described in I), represented by the formula (II):
wherein R
8
, R
9
, R
10
, and R
11
are each independently hydrogen atom, optionally substituted alkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, a non-aromatic heterocyclic group, acyl, optionally substituted amino, alkyloxy, hydroxy, cyano, or nitro;
R
B
and R
C
are each independently hydrogen atom, alkyl, or alkyloxy; provided that in the case of both of R
B
and R
C
are hydrogen atom, R
8
is hydrogen atom or alkyl, R
9
is substituted amino, alkyloxy, hydroxy, cyano, or nitro; and R
10
and R
11
are each independently hydrogen atom, optionally substituted alkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, non-aromatic heterocyclic group, acyl, optionally substituted amino, alkyloxy, hydroxy, cyano, or nitro;
W is —O—, —S—, or —N(R
A
)— wherein R
A
is hydrogen atom or optionally substituted alkyl;
R
5
, R
6
, X, and Z are as defined above mentioned I); its optical active compound, its prodrug thereof, or their pharmaceutically acceptable salt, or their solvate.
III) a compound described in I), represented by the formula (III):
wherein R
5
, R
6
, and Z are as defined above mentioned I); R
8
, R
9
, R
10
, R
11
, R
B
and R
C
are as defined above mentioned II);
its optical active compound, its prodrug thereof, or their pharmaceutically acceptable salt, or their solvate.
IV) a compound described in I), represented by the formula (IV):
wherein R
8
, R
9
, R
10
and R
11
are as defined above mentioned II);
R
12
is hydrogen atom or alkyl;
R
D
and R
E
are each independently hydrogen atom or alkyl; provided that in the case of both of R
D
and R
E
are hydrogen atom, R
8
is hydrogen atom or alkyl, R
9
is optionally substituted amino, alkyloxy, hydroxy, cyano, or nitro; and R
10
and R
11
are each independently hydrogen atom, optionally substituted alkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, non-aromatic heterocyclic group, acyl, optionally substituted amino, alkyloxy, hydroxy, cyano, or nitro;
V is optionally substituted aryl; its optical active compound, its prodrug thereof, or their pharmaceutically acceptable salt, or their solvate.
V) a compound represented by the formula (V):
wherein R
5
and R
6
are each independently hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkyloxy, alkylthio, optionally substituted alkyloxycarbonyl, optionally substituted aryl, optionally substituted heteroaryl, halogen atoms, hydroxy, mercapto, optionally substituted amino, carboxy, cyano, or nitro;
R
F
and R
G
are each independently
Suzuki Shinji
Takenaka Hideyuki
Tanaka Hidekazu
Ueda Kazuo
Birch & Stewart Kolasch & Birch, LLP
McKenzie Thomas
Shionogi & Co. Ltd.
LandOfFree
Pyrimidine derivatives having antitumor effect does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine derivatives having antitumor effect, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine derivatives having antitumor effect will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3287997